Best Penny Stocks to Buy on Robinhood Right Now? 4 To Check Out
Looking for the best penny stocks on Robinhood? Check these 4 out and decide for yourself
The post Best Penny Stocks to Buy on Robinhood Right Now? 4 To Check Out appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Are These 4 Robinhood Penny Stocks Ready to Take Flight?
Robinhood penny stocks have become some of the most trending stocks to watch in the past few months. There are a few reasons why this is the case. For one, there are hundreds of options when it comes to finding penny stocks on Robinhood.
Because the term ‘penny stocks’ itself, applies to any stocks under $5, you can see the options are aplenty. The second reason is that Robinhood is one of the most accessible trading platforms out there. With zero commission trades and an easy-to-use platform, Robinhood essentially democratized trading when it first became popular.
Now it’s worth noting that the brokerage has its ups and downs. It has been known to halt trading in times of massively heightened volume, and this has not pleased investors. However, we can’t deny that the existence of Robinhood has fundamentally changed trading penny stocks and blue chips as well.
So, because of this, many investors have turned to Robinhood to buy and sell stocks under $5 because of its $0 commission fees. And while many brokerages have followed suit, Robinhood remains one of the most popular among under 35 investors. So with all of this in mind, let’s take look at four of the best penny stocks to watch on Robinhood right now.
4 Robinhood Penny Stocks to Watch
Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP)
1. Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP)
Corbus Pharmaceuticals Holdings Inc. is a leading biotech and marijuana stock that has performed quite well in the past few weeks. You may be wondering, what does Corbus Pharmaceuticals Holdings do?
This company is focused on the development and commercialization of novel therapeutics that target autoimmune disorders, fibrosis, and cancer. These endocannabinoid system products include its lead candidate lenabasum, which is a cannabinoid receptor type 2 medicine in Phase III trials.
Corbus has plans to present at three upcoming conferences. These include the 2021 RBC Capital Markets Global Healthcare Conference, Oppenheimer Rare & Orphan Disease Summit, and the Jefferies Virtual Global Healthcare Conference. Ahead of these conferences, CRBP stock is up 24% on May 14th. It seems like investors have a bullish sentiment about CRBP ahead of its upcoming announcements.
Just last month the company also announced the completion of enrollment for its Phase 2 study of Lenabasum for treating systemic lupus erythematosus. The study, sponsored and funded by the National Institute of Allergy and Infectious Diseases, will take place over 16 weeks. Patients will be given either 20 mg twice daily, 20 mg once daily, 5mg twice daily, or placebo.
As you can see, Corbus has a lot in its pipeline. This could make CRBP a more attractive option to long-term and short-term penny stock investors. This penny stock has experienced many ups and downs in 2021, which illustrates how volatile it is.
With prices moving frequently, investors should remember that things can often get risky. But if you are careful in how you invest, this risk can be mitigated. With this in mind, is CRBP on your list of penny stocks to watch?
2. Meten EdtechX Education Group Ltd. (NASDAQ: METX)
Meten EdtechX Education Group Ltd. is a tech penny stock that provides English language training services in China. The company provides its services in four different ways. This includes general adult English training, overseas training services, online English training, and junior English training. Currently, it operates 105 learning centers in 28 cities and 15 provinces in China.
The company intends on reporting its first-quarter financial results on Thursday, May 20th. This does not mean there aren’t other updates that have come from Meten. The company did report on May 12th that it has achieved positive cash flow in March 2021. This operating cash flow was generated because of increasing gross billing generated by its offline learning centers since it has recovered operation after the pandemic.
It intends on continuing this by closing poorly performing stores and letting go of employees as well as increasing its sales through the optimization of its incentive plan. It also plans on increasing the efficiency of its marketing. In the first quarter of 2021, Meten saw a 485% increase in gross billing and a 483% increase in student enrollment of its junior English language training business. The company expects to grow 82% in gross billing this year.
If you’ve been finding penny stocks to watch recently, you will know that many have gotten involved in blockchain technology. While Meten is not a pure play blockchain penny stock, it is working to get involved. The company is planning to make full use of blockchain technology with its offerings. The company has placed a focus on accelerating technological innovation and digital transformation of online education via blockchain.
It would be able to give students transparent, credible, and tamper-proof digital certificates to mitigate academic dishonesty. This could turn out to be widely used in all types of education sections. When taking exams, for example, the company could ensure that no cheating occurs using its digital platform. With all of these advancements in mind, is METX on your penny stock watchlist?
3. Minerva Neurosciences Inc. (NASDAQ: NERV)
The biotech company, Minerva Neurosciences Inc., focuses on developing and commercializing central nervous system disease treatment products. Its lead product is roluperidone which is a compound that is in Phase III trials to treat schizophrenia. It is working on treatments for Parkinson’s as well.
On May 12th the company reported its 2021 financial results and business updates. Its results for its schizophrenia trial are very positive. It is seeing a continuous improvement in negative symptoms, continuous improvement in personal and social performance, and has a favorable safety profile.
“The results of the open-label extension of the phase 3 trial with roluperidone provide additional support for the continued development of this agent, particularly in an environment with a continuing significant unmet medical need for schizophrenia treatments with novel mechanisms of action.”
Dr. Remy Luthringer, Executive Chairman and CEO of Minerva
For its financial results, its net less fell a lot year over year from $12.2 million to $8.8 million. After this promising schizophrenia study data was released, the company’s stock price has soared. NERV stock is up 5.5% on May 14th, and up about 25% in the last 5 days.
This has placed a bullish sentiment on Minerva that has caused its volume to be about 1.2 million higher than average. Its new encouraging data should support a New Drug Application to the FDA following the completion of a bioequivalence study. With all of this information in mind, will you invest in NERV for your penny stock watchlist?
4. Akebia Therapeutics Inc. (NASDAQ: AKBA)
Akebia Therapeutics Inc. focuses on the development and commercialization of renal therapeutics. These are in use to treat patients that have a range of kidney diseases. One of its main products is vadadustat, which is an oral therapy in Phase III development to treat anemia caused by chronic kidney disease. It also has Auryxia which is aferric citrate-based medicine used to control serum phosphorus levels in adults with CKD on dialysis.
When May 10th came around, Akebia released its first-quarter 2021 financial results and highlighted its recent company milestones. It submitted a New Drug Application or NDA to the U.S. Food and Drug Administration for Vadadustat during this period.
“Akebia is off to a great start in 2021, building positive momentum with solid execution on strategic priorities that set the stage for an exciting year. Most importantly, we submitted the vadadustat NDA to the FDA, a significant milestone for Akebia and our partner, Otsuka Pharmaceutical Co. Ltd.
We are also very proud that the New England Journal of Medicine recently published the results from both INNO2VATE and PRO2TECT, the global Phase 3 programs for vadadustat.”
The CEO of Akebia, John P. Butler
In regards to its financials, its total revenue fell year over year because of lower collaboration revenue. This is because of the completion of two of its Phase 3 clinical programs. For the same reason, its R&D expenses fell year over year. Its net loss also increased for similar reasons.
The company believes that despite the negative impact of COVID-19 on its business, it has favorable odds for the future. The company is still being cautious with the pandemic going on, but it states that it could have product revenue growth in 2021. AKBA stock has increased in value by about 17% since this report was released.
Does this mean that AKBA will continue to grow in 2021? This is uncertain, but we will know more about where the company stands when its next update is released. Will AKBA stock make your list of penny stocks to watch this month?
Are These Penny Stocks on Robinhood Worth It?
Finding the hottest penny stocks on Robinhood can be a challenge for some. If you don’t know what you’re looking for, it can be easy to get lost and end up in the red. However, with a trading education and a dedication to learning as much as you can, buying and selling penny stocks on Robinhood can be easy.
In addition, investors should use the tools at their disposal to figure out if certain stocks align with their portfolios and investing styles. Considering all of this, are these Robinhood penny stocks worth it?
Mathematicians use AI to identify emerging COVID-19 variants
Scientists at The Universities of Manchester and Oxford have developed an AI framework that can identify and track new and concerning COVID-19 variants…
Scientists at The Universities of Manchester and Oxford have developed an AI framework that can identify and track new and concerning COVID-19 variants and could help with other infections in the future.
Scientists at The Universities of Manchester and Oxford have developed an AI framework that can identify and track new and concerning COVID-19 variants and could help with other infections in the future.
The framework combines dimension reduction techniques and a new explainable clustering algorithm called CLASSIX, developed by mathematicians at The University of Manchester. This enables the quick identification of groups of viral genomes that might present a risk in the future from huge volumes of data.
The study, presented this week in the journal PNAS, could support traditional methods of tracking viral evolution, such as phylogenetic analysis, which currently require extensive manual curation.
Roberto Cahuantzi, a researcher at The University of Manchester and first and corresponding author of the paper, said: “Since the emergence of COVID-19, we have seen multiple waves of new variants, heightened transmissibility, evasion of immune responses, and increased severity of illness.
“Scientists are now intensifying efforts to pinpoint these worrying new variants, such as alpha, delta and omicron, at the earliest stages of their emergence. If we can find a way to do this quickly and efficiently, it will enable us to be more proactive in our response, such as tailored vaccine development and may even enable us to eliminate the variants before they become established.”
Like many other RNA viruses, COVID-19 has a high mutation rate and short time between generations meaning it evolves extremely rapidly. This means identifying new strains that are likely to be problematic in the future requires considerable effort.
Currently, there are almost 16 million sequences available on the GISAID database (the Global Initiative on Sharing All Influenza Data), which provides access to genomic data of influenza viruses.
Mapping the evolution and history of all COVID-19 genomes from this data is currently done using extremely large amounts of computer and human time.
The described method allows automation of such tasks. The researchers processed 5.7 million high-coverage sequences in only one to two days on a standard modern laptop; this would not be possible for existing methods, putting identification of concerning pathogen strains in the hands of more researchers due to reduced resource needs.
Thomas House, Professor of Mathematical Sciences at The University of Manchester, said: “The unprecedented amount of genetic data generated during the pandemic demands improvements to our methods to analyse it thoroughly. The data is continuing to grow rapidly but without showing a benefit to curating this data, there is a risk that it will be removed or deleted.
“We know that human expert time is limited, so our approach should not replace the work of humans all together but work alongside them to enable the job to be done much quicker and free our experts for other vital developments.”
The proposed method works by breaking down genetic sequences of the COVID-19 virus into smaller “words” (called 3-mers) represented as numbers by counting them. Then, it groups similar sequences together based on their word patterns using machine learning techniques.
Stefan Güttel, Professor of Applied Mathematics at the University of Manchester, said: “The clustering algorithm CLASSIX we developed is much less computationally demanding than traditional methods and is fully explainable, meaning that it provides textual and visual explanations of the computed clusters.”
Roberto Cahuantzi added: “Our analysis serves as a proof of concept, demonstrating the potential use of machine learning methods as an alert tool for the early discovery of emerging major variants without relying on the need to generate phylogenies.
“Whilst phylogenetics remains the ‘gold standard’ for understanding the viral ancestry, these machine learning methods can accommodate several orders of magnitude more sequences than the current phylogenetic methods and at a low computational cost.”
Journal
Proceedings of the National Academy of Sciences
DOI
10.1073/pnas.2317284121
Article Title
Unsupervised identification of significant lineages of SARS-CoV-2 through scalable machine learning methods
While the size of the United States makes it hard for it to compete with the inter-city train access available in places like Japan and many European countries, Amtrak trains are a very popular transportation option in certain pockets of the country — so much so that the country’s national railway company is expanding its Northeast Corridor by more than one million seats.
Running from Boston all the way south to Washington, D.C., the route is one of the most popular as it passes through the most densely populated part of the country and serves as a commuter train for those who need to go between East Coast cities such as New York and Philadelphia for business.
Veronika Bondarenko captured this photo of New York’s Moynihan Train Hall.
Veronika Bondarenko
Amtrak launches new routes, promises travelers ‘additional travel options’
Earlier this month, Amtrak announced that it was adding four additional Northeastern routes to its schedule — two more routes between New York’s Penn Station and Union Station in Washington, D.C. on the weekend, a new early-morning weekday route between New York and Philadelphia’s William H. Gray III 30th Street Station and a weekend route between Philadelphia and Boston’s South Station.
According to Amtrak, these additions will increase Northeast Corridor’s service by 20% on the weekdays and 10% on the weekends for a total of one million additional seats when counted by how many will ride the corridor over the year.
“More people are taking the train than ever before and we’re proud to offer our customers additional travel options when they ride with us on the Northeast Regional,” Amtrak Executive Vice President and Chief Commercial Officer Eliot Hamlisch said in a statement on the new routes. “The Northeast Regional gets you where you want to go comfortably, conveniently and sustainably as you breeze past traffic on I-95 for a more enjoyable travel experience.”
Here are some of the other Amtrak changes you can expect to see
Amtrak also said that, in the 2023 financial year, the Northeast Corridor had nearly 9.2 million riders — 8% more than it had pre-pandemic and a 29% increase from 2022. The higher demand, particularly during both off-peak hours and the time when many business travelers use to get to work, is pushing Amtrak to invest into this corridor in particular.
To reach more customers, Amtrak has also made several changes to both its routes and pricing system. In the fall of 2023, it introduced a type of new “Night Owl Fare” — if traveling during very late or very early hours, one can go between cities like New York and Philadelphia or Philadelphia and Washington. D.C. for $5 to $15.
As travel on the same routes during peak hours can reach as much as $300, this was a deliberate move to reach those who have the flexibility of time and might have otherwise preferred more affordable methods of transportation such as the bus. After seeing strong uptake, Amtrak added this type of fare to more Boston routes.
The largest distances, such as the ones between Boston and New York or New York and Washington, are available at the lowest rate for $20.
I am a conservation biologist who studies emerging infectious diseases. When people ask me what I think the next pandemic will be I often say that we are in the midst of one – it’s just afflicting a great many species more than ours.
I am referring to the highly pathogenic strain of avian influenza H5N1 (HPAI H5N1), otherwise known as bird flu, which has killed millions of birds and unknown numbers of mammals, particularly during the past three years.
This is the strain that emerged in domestic geese in China in 1997 and quickly jumped to humans in south-east Asia with a mortality rate of around 40-50%. My research group encountered the virus when it killed a mammal, an endangered Owston’s palm civet, in a captive breeding programme in Cuc Phuong National Park Vietnam in 2005.
How these animals caught bird flu was never confirmed. Their diet is mainly earthworms, so they had not been infected by eating diseased poultry like many captive tigers in the region.
This discovery prompted us to collate all confirmed reports of fatal infection with bird flu to assess just how broad a threat to wildlife this virus might pose.
This is how a newly discovered virus in Chinese poultry came to threaten so much of the world’s biodiversity.
Until December 2005, most confirmed infections had been found in a few zoos and rescue centres in Thailand and Cambodia. Our analysis in 2006 showed that nearly half (48%) of all the different groups of birds (known to taxonomists as “orders”) contained a species in which a fatal infection of bird flu had been reported. These 13 orders comprised 84% of all bird species.
We reasoned 20 years ago that the strains of H5N1 circulating were probably highly pathogenic to all bird orders. We also showed that the list of confirmed infected species included those that were globally threatened and that important habitats, such as Vietnam’s Mekong delta, lay close to reported poultry outbreaks.
Mammals known to be susceptible to bird flu during the early 2000s included primates, rodents, pigs and rabbits. Large carnivores such as Bengal tigers and clouded leopards were reported to have been killed, as well as domestic cats.
Our 2006 paper showed the ease with which this virus crossed species barriers and suggested it might one day produce a pandemic-scale threat to global biodiversity.
In the past couple of years, bird flu has spread rapidly across Europe and infiltrated North and South America, killing millions of poultry and a variety of bird and mammal species. A recent paper found that 26 countries have reported at least 48 mammal species that have died from the virus since 2020, when the latest increase in reported infections started.
Not even the ocean is safe. Since 2020, 13 species of aquatic mammal have succumbed, including American sea lions, porpoises and dolphins, often dying in their thousands in South America. A wide range of scavenging and predatory mammals that live on land are now also confirmed to be susceptible, including mountain lions, lynx, brown, black and polar bears.
The UK alone has lost over 75% of its great skuas and seen a 25% decline in northern gannets. Recent declines in sandwich terns (35%) and common terns (42%) were also largely driven by the virus.
Scientists haven’t managed to completely sequence the virus in all affected species. Research and continuous surveillance could tell us how adaptable it ultimately becomes, and whether it can jump to even more species. We know it can already infect humans – one or more genetic mutations may make it more infectious.
At the crossroads
Between January 1 2003 and December 21 2023, 882 cases of human infection with the H5N1 virus were reported from 23 countries, of which 461 (52%) were fatal.
Of these fatal cases, more than half were in Vietnam, China, Cambodia and Laos. Poultry-to-human infections were first recorded in Cambodia in December 2003. Intermittent cases were reported until 2014, followed by a gap until 2023, yielding 41 deaths from 64 cases. The subtype of H5N1 virus responsible has been detected in poultry in Cambodia since 2014. In the early 2000s, the H5N1 virus circulating had a high human mortality rate, so it is worrying that we are now starting to see people dying after contact with poultry again.
It’s not just H5 subtypes of bird flu that concern humans. The H10N1 virus was originally isolated from wild birds in South Korea, but has also been reported in samples from China and Mongolia.
Recent research found that these particular virus subtypes may be able to jump to humans after they were found to be pathogenic in laboratory mice and ferrets. The first person who was confirmed to be infected with H10N5 died in China on January 27 2024, but this patient was also suffering from seasonal flu (H3N2). They had been exposed to live poultry which also tested positive for H10N5.
Species already threatened with extinction are among those which have died due to bird flu in the past three years. The first deaths from the virus in mainland Antarctica have just been confirmed in skuas, highlighting a looming threat to penguin colonies whose eggs and chicks skuas prey on. Humboldt penguins have already been killed by the virus in Chile.
How can we stem this tsunami of H5N1 and other avian influenzas? Completely overhaul poultry production on a global scale. Make farms self-sufficient in rearing eggs and chicks instead of exporting them internationally. The trend towards megafarms containing over a million birds must be stopped in its tracks.
To prevent the worst outcomes for this virus, we must revisit its primary source: the incubator of intensive poultry farms.
Diana Bell does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
